DAX21.206 -0,5%ESt504.935 -0,6%Top 10 Crypto11,33 +4,4%Dow39.142 -1,3%Nas16.286 -0,1%Bitcoin74.320 -0,4%Euro1,1375 ±0,0%Öl67,85 +2,7%Gold3.328 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Siemens Energy ENER6Y Tesla A1CX3T Novo Nordisk A3EU6F RENK RENK73 Amazon 906866 Apple 865985 Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 Volkswagen (VW) vz. 766403 Allianz 840400 BASF BASF11 UnitedHealth 869561 Infineon 623100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach EZB-Entscheid: DAX geht leichter ins lange Osterwochenende -- Netflix mit Gewinnplus -- EZB senkt Leitzins -- Siemens Energy, TSMC, NVIDIA, ASML, UnitedHealth, Hertz im Fokus
Top News
Silberpreis, Goldpreis & Co. aktuell: So steht es am Freitagmittag um die Kurse der Rohstoffe Silberpreis, Goldpreis & Co. aktuell: So steht es am Freitagmittag um die Kurse der Rohstoffe
Bayer-Chef: Glyphosat-Stopp in den USA ist denkbar Bayer-Chef: Glyphosat-Stopp in den USA ist denkbar
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
"600% Momentum-Strategie": Aktien hebeln und Gewinne maximieren - sichern Sie sich jetzt das Kennenlernangebot für nur 39 Euro (statt 69 Euro) im Monat!

CSL Aktie

NeuKaufenVerkaufen
CSL Aktien-Sparplan
132,98 EUR -0,54 EUR -0,40 %
FSE
241,89 AUD -2,21 AUD -0,91 %
AUSX
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.65,00 Mrd. EUR

KGV35,37Div. Rendite1,35%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN890952

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINAU000000CSL8

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCMXHF

CSL Aktien News

DatumMeistgelesen
PR NewswireCSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks...
PR NewswireEuropean Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
PR NewswireEuropean Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
Wer­bungCSL-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireCSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
PR NewswireTavneos® (Avacopan) in der Schweiz jetzt erstattet für die Behandlung der ANCA-assoziierten Vaskulitis
PR NewswireCSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
PR NewswireNew Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines
PR NewswireCSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
PR NewswireCSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
PR NewswireSelf-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
PR NewswireCSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireJapan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan b...
PR NewswireCSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
PR NewswireCSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season
PR NewswireCSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza
PR NewswireNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
PR NewswireRecently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Wer­bung

CSL News

CSL News: auf dieser Seite finden Sie alle CSL News und Nachrichten zur CSL Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CSL News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CSL News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.